These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 33430645)

  • 1. Omaveloxolone: potential new agent for Friedreich ataxia.
    Lynch DR; Johnson J
    Neurodegener Dis Manag; 2021 Apr; 11(2):91-98. PubMed ID: 33430645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omaveloxolone: an activator of Nrf2 for the treatment of Friedreich ataxia.
    Profeta V; McIntyre K; Wells M; Park C; Lynch DR
    Expert Opin Investig Drugs; 2023 Jan; 32(1):5-16. PubMed ID: 36708320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapeutic strategies for Friedreich Ataxia: a review of the available data.
    Gunther K; Lynch DR
    Expert Opin Pharmacother; 2024 Apr; 25(5):529-539. PubMed ID: 38622054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omaveloxolone: a groundbreaking milestone as the first FDA-approved drug for Friedreich ataxia.
    Pilotto F; Chellapandi DM; Puccio H
    Trends Mol Med; 2024 Feb; 30(2):117-125. PubMed ID: 38272714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omaveloxolone for the treatment of Friedreich ataxia: clinical trial results and practical considerations.
    Lynch DR; Perlman S; Schadt K
    Expert Rev Neurother; 2024 Mar; 24(3):251-258. PubMed ID: 38269532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Designing phase II clinical trials in Friedreich ataxia.
    Rodden LN; Lynch DR
    Expert Opin Emerg Drugs; 2021 Dec; 26(4):415-423. PubMed ID: 34693848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia.
    Lynch DR; Farmer J; Hauser L; Blair IA; Wang QQ; Mesaros C; Snyder N; Boesch S; Chin M; Delatycki MB; Giunti P; Goldsberry A; Hoyle C; McBride MG; Nachbauer W; O'Grady M; Perlman S; Subramony SH; Wilmot GR; Zesiewicz T; Meyer C
    Ann Clin Transl Neurol; 2019 Jan; 6(1):15-26. PubMed ID: 30656180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study).
    Lynch DR; Chin MP; Delatycki MB; Subramony SH; Corti M; Hoyle JC; Boesch S; Nachbauer W; Mariotti C; Mathews KD; Giunti P; Wilmot G; Zesiewicz T; Perlman S; Goldsberry A; O'Grady M; Meyer CJ
    Ann Neurol; 2021 Feb; 89(2):212-225. PubMed ID: 33068037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of the novel Nrf2 activator omaveloxolone in primates.
    Reisman SA; Gahir SS; Lee CI; Proksch JW; Sakamoto M; Ward KW
    Drug Des Devel Ther; 2019; 13():1259-1270. PubMed ID: 31118567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological therapeutics in Friedreich ataxia: the present state.
    Strawser C; Schadt K; Hauser L; McCormick A; Wells M; Larkindale J; Lin H; Lynch DR
    Expert Rev Neurother; 2017 Sep; 17(9):895-907. PubMed ID: 28724340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging therapies in Friedreich's Ataxia.
    Zesiewicz TA; Hancock J; Ghanekar SD; Kuo SH; Dohse CA; Vega J
    Expert Rev Neurother; 2020 Dec; 20(12):1215-1228. PubMed ID: 32909841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An RNA-seq study in Friedreich ataxia patients identified hsa-miR-148a-3p as a putative prognostic biomarker of the disease.
    Vancheri C; Quatrana A; Morini E; Mariotti C; Mongelli A; Fichera M; Rufini A; Condò I; Testi R; Novelli G; Malisan F; Amati F
    Hum Genomics; 2024 May; 18(1):50. PubMed ID: 38778374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Milestone in the Treatment of Ataxias: Approval of Omaveloxolone for Friedreich Ataxia.
    Subramony SH; Lynch DL
    Cerebellum; 2024 Apr; 23(2):775-777. PubMed ID: 37219716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Friedreich ataxia: clinical features and new developments.
    Keita M; McIntyre K; Rodden LN; Schadt K; Lynch DR
    Neurodegener Dis Manag; 2022 Oct; 12(5):267-283. PubMed ID: 35766110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New developments in pharmacotherapy for Friedreich ataxia.
    Clay A; Hearle P; Schadt K; Lynch DR
    Expert Opin Pharmacother; 2019 Oct; 20(15):1855-1867. PubMed ID: 31311349
    [No Abstract]   [Full Text] [Related]  

  • 16. Omaveloxolone: First Approval.
    Lee A
    Drugs; 2023 Jun; 83(8):725-729. PubMed ID: 37155124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history data.
    Lynch DR; Goldsberry A; Rummey C; Farmer J; Boesch S; Delatycki MB; Giunti P; Hoyle JC; Mariotti C; Mathews KD; Nachbauer W; Perlman S; Subramony SH; Wilmot G; Zesiewicz T; Weissfeld L; Meyer C
    Ann Clin Transl Neurol; 2024 Jan; 11(1):4-16. PubMed ID: 37691319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small molecules affecting transcription in Friedreich ataxia.
    Gottesfeld JM
    Pharmacol Ther; 2007 Nov; 116(2):236-48. PubMed ID: 17826840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of rehabilitation intervention in persons with Friedreich ataxia.
    Paparella G; Stragà C; Vavla M; Pesenti N; Merotto V; Martorel GA; Zalunardo S; Armellin M; Comiotto J; Martinuzzi A
    Front Neurol; 2023; 14():1270296. PubMed ID: 38020600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Omaveloxolone in Friedreich's Ataxia: Delayed-Start Analysis of the MOXIe Extension.
    Lynch DR; Chin MP; Boesch S; Delatycki MB; Giunti P; Goldsberry A; Hoyle JC; Mariotti C; Mathews KD; Nachbauer W; O'Grady M; Perlman S; Subramony SH; Wilmot G; Zesiewicz T; Meyer CJ
    Mov Disord; 2023 Feb; 38(2):313-320. PubMed ID: 36444905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.